CN114425075A - New application of Xiaochaihu granules in preventing and treating infantile indigestion with food retention - Google Patents
New application of Xiaochaihu granules in preventing and treating infantile indigestion with food retention Download PDFInfo
- Publication number
- CN114425075A CN114425075A CN202210138796.1A CN202210138796A CN114425075A CN 114425075 A CN114425075 A CN 114425075A CN 202210138796 A CN202210138796 A CN 202210138796A CN 114425075 A CN114425075 A CN 114425075A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- ginger
- chinese
- active ingredients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 25
- 239000008767 xiaochaihu Substances 0.000 title claims abstract description 15
- 235000013305 food Nutrition 0.000 title claims abstract description 14
- 201000006549 dyspepsia Diseases 0.000 title claims abstract description 12
- 230000014759 maintenance of location Effects 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 30
- 241000700159 Rattus Species 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 230000002496 gastric effect Effects 0.000 claims abstract description 10
- 230000028327 secretion Effects 0.000 claims abstract description 9
- 230000001737 promoting effect Effects 0.000 claims abstract description 5
- 241000234314 Zingiber Species 0.000 claims description 28
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 28
- 235000008397 ginger Nutrition 0.000 claims description 28
- 241001522129 Pinellia Species 0.000 claims description 14
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 13
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims description 13
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims description 13
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 13
- 235000011477 liquorice Nutrition 0.000 claims description 13
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 11
- 241000007126 Codonopsis pilosula Species 0.000 claims description 5
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 4
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 241000756943 Codonopsis Species 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 240000000038 Ziziphus mauritiana Species 0.000 claims 2
- 241001132254 Bupleurum tenue Species 0.000 abstract description 9
- 239000002245 particle Substances 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 6
- 235000005911 diet Nutrition 0.000 abstract description 3
- 230000037213 diet Effects 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 230000030136 gastric emptying Effects 0.000 description 11
- 210000000813 small intestine Anatomy 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 6
- 229960005132 cisapride Drugs 0.000 description 6
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000008227 sterile water for injection Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000202726 Bupleurum Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000207929 Scutellaria Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241001522232 Pinellia ternata Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of a traditional Chinese medicine composition in preparing a medicine for preventing and treating infantile indigestion with food retention. The traditional Chinese medicine composition is bupleurum tenue particles. Experiments are carried out by adopting an FD model caused by chronic constraint stress, excessive fatigue and diet malunion, and the bupleurum tenue particles are found to be capable of promoting gastric secretion of young rats, so that dyspepsia symptoms of the young rats are relieved. Therefore, the Xiaochaihu granules can be applied to preventing and treating infantile indigestion with food retention.
Description
Technical Field
The invention belongs to the field of Chinese patent medicine application, and particularly relates to a new application of a Chinese medicinal composition, namely Xiaochaihu granules in preventing and treating infantile indigestion with food retention.
Background
The digestive system and the immune system of the children are not mature, and in addition, the children cannot adjust their diets, hunger and satiety cannot be adjusted automatically, and the children are easy to suffer from indigestion due to long-term eating disorder.
The infantile indigestion is the name of the disease syndrome, which is reported in Yi Zong jin Jian, essential formula of heart method of infant science. This is the syndrome of food retention in children manifested as warm head and abdomen, foul stool, belching, aversion to food, restlessness, insomnia, dry mouth and thirst. Food stagnation is one of common diseases of children, and other diseases such as fever, cold, acute pharyngolaryngitis, constipation and the like are easily caused due to food stagnation.
Xiaochaihu decoction is one of eight famous prescriptions in traditional Chinese medicine, and is a representative prescription of Shaoyang disease in Shang Han miscellaneous diseases treatise on Sheng Zhang Zhong Jing (medical science). The bupleurum tenue particles are a granular Chinese patent medicine preparation which is prepared by Guangzhou Baiyunshanguanhua pharmacy according to the first family of Xiaochaihu decoction, is prepared from seven medicinal herbs including bupleurum, scutellaria, pinellia (processed by ginger), codonopsis pilosula, ginger, liquorice and Chinese date according to the prescription of 'monarch, minister, assistant and guide' and is used for treating exogenous diseases and the syndrome of pathogen attacking shaoyang, which is characterized by alternating cold and heat, fullness in chest and hypochondrium, inappetence, dysphoria with joy and vomiting and bitter taste and dry throat. In the formula, the bupleurum root disperses pathogenic factors to the exterior, so that the pathogenic factors in the half exterior can be diffused from the exterior, and the scutellaria root clears heat, so that the pathogenic factors in the half interior can be dispersed from the interior; pinellia ternata clears away phlegm and lowers turbid qi to arrest vomiting; ginseng radix has effects of invigorating qi and strengthening body resistance, and Glycyrrhrizae radix has effects of regulating stomach; the ginger and the jujube can help shaoyang grow qi and prevent the transmission of pathogenic factors.
Disclosure of Invention
The invention aims to provide a new application of a traditional Chinese medicine composition prepared from radix bupleuri, radix scutellariae, pinellia ternate (processed with ginger), radix codonopsitis, ginger, liquorice and Chinese date.
The technical scheme is as follows.
An application of a Chinese medicinal composition in preparing a medicament for preventing and treating infantile indigestion with food retention is disclosed, wherein the active ingredients of the Chinese medicinal composition are prepared from radix bupleuri, radix scutellariae, ginger processed pinellia tuber, radix codonopsis pilosulae, ginger, liquorice and Chinese date.
In one embodiment, the active ingredients of the traditional Chinese medicine composition are prepared from the following raw materials in parts by weight: 150 +/-5 parts of radix bupleuri, 56 +/-5 parts of radix scutellariae, 56 +/-5 parts of ginger processed pinellia, 56 +/-5 parts of radix codonopsitis, 56 +/-5 parts of ginger, 56 +/-5 parts of liquorice and 56 +/-5 parts of Chinese date.
In some preferred embodiments, the active ingredients of the traditional Chinese medicine composition comprise, by weight: 150 parts of radix bupleuri, 56 parts of scutellaria baicalensis, 56 parts of ginger processed pinellia, 56 parts of codonopsis pilosula, 56 parts of ginger, 56 parts of liquorice and 56 parts of Chinese dates.
In some preferred embodiments, the dosage form of the drug is decoction, fluid extract or granule.
In some preferred embodiments, the dosage form of the traditional Chinese medicine composition is granules.
In some preferred embodiments, the Chinese medicinal composition is bupleurum tenue particles.
The invention also aims to provide application of the traditional Chinese medicine composition in preparing a medicine for promoting gastric secretion of children or young rats.
The inventor discovers in the study of young rats that the traditional Chinese medicine composition consisting of radix bupleuri, scutellaria baicalensis, ginger processed pinellia, codonopsis pilosula, ginger, liquorice and Chinese date, in particular the small radix bupleuri granules, have the function of obviously promoting gastric secretion and can assist the digestion function, so that the small radix bupleuri granules have a good prevention and treatment effect on infantile indigestion with food retention.
Drawings
FIG. 1 is a bar graph of the effect of small bupleurum particles on the gastric emptying rate and small intestinal transit rate of young rats in example 1 of the present invention, wherein A: the rate of gastric emptying; b: rate of small intestine propulsion.
FIG. 2 is a schematic representation of the molding and administration timeline of example 1 of the present invention.
FIG. 3 is a bar graph of the effect of bupleurum tenue particles on gastric secretion in young rats, wherein, total amount of gastric juice A; b: total acidity; c: total acid output.
Detailed Description
The following examples of the present invention are experimental methods without specifying specific conditions, generally according to conventional conditions, or according to conditions recommended by the manufacturer. The various chemicals used in the examples are commercially available.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The "plurality" referred to in the present invention means two or more. "and/or" describes the association relationship of the associated objects, meaning that there may be three relationships, e.g., a and/or B, which may mean: a exists alone, A and B exist simultaneously, and B exists alone. The character "/" generally indicates that the former and latter associated objects are in an "or" relationship.
In order that the invention may be more fully understood, reference will now be made to the following description. The following examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the following examples, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and essential concept of the present invention should be construed as equivalents thereof, and are intended to be included in the scope of the present invention.
The traditional Chinese medicine composition comprises the following active ingredients: 150 +/-5 parts of radix bupleuri, 56 +/-5 parts of radix scutellariae, 56 +/-5 parts of ginger processed pinellia, 56 +/-5 parts of radix codonopsitis, 56 +/-5 parts of ginger, 56 +/-5 parts of liquorice and 56 +/-5 parts of Chinese date.
The traditional Chinese medicine composition used in the following preferred embodiments is bupleurum tenue granules sold by Guangzhou Baiyunshan Guanghua pharmaceutical GmbH, and the active ingredients specifically comprise: 150g of radix bupleuri, 56g of radix scutellariae, 56g of ginger processed pinellia, 56g of radix codonopsitis, 56g of ginger, 56g of liquorice and 56g of Chinese date, and the preparation is granules.
Example 1: effect of Xiaochaihu granules on gastrointestinal motility of young rats
1. Experimental Material
1.1 Experimental animals
65 weaned (3 weeks old) SD juvenile rats, male, SPF grade, body weight 60-70g, obtained from Shanghai Si-Rick laboratory animals GmbH (quality of laboratory animals: 20170005049510; production permit for laboratory animals: SCXK (Shanghai) 2017-. Each squirrel cage is hung with an identity card with information such as project numbers, experimental groups, names of experimenters, animal species, sexes and the like, and the tail root of the rat is marked with a line. The young rats are raised in an animal room at the raising temperature of 23 +/-2 ℃, the relative humidity of 40-70 percent and the light and shade alternation time of 12 hours. Animals were housed 5 per cage with two bedding changes per week (corncob bedding, dam Chuan commerce Co., Ltd., Suzhou). The adaptation period (3 days) was fed with SPF rat growth and reproduction feed (Co60 sterilized and purchased from Australian cooperative feed Co., Beijing, Kyoco.). The water for the experimental animal is filtered by autoclaving. Animals used for the experiment will remain healthy. Animals had free access to food and water during the experiment.
1.2 Experimental drugs
The tested drugs are: small radix bupleuri granule (origin: Guangzhou Baiyunshan Guanghua pharmaceutical GmbH; national standard: Z44020211; specification: 10g x 10 bags)
Positive drug: cisapride (source: Ningbo Dahong eagle pharmaceutical Co., Ltd.; Specification: 10 mg/tablet 10 tablets)
Blank control: sterilized water for injection (origin: Guangdong Axide pharmaceutical Co., Ltd.; Specification: 500 ml/bottle)
1.3 Experimental reagents
Sodium carboxymethylcellulose (CMC-Na) (source: aladdin; viscosity: 800-
2 method of experiment
2.1 Experimental groups and dosing regimens
2.1.1 basis for dose selection
Clinical dose (adult): 1-2 bags at a time, 3 times a day. The high dose and the low dose were increased and decreased 2-fold respectively, with 2 bags/dose and 3 times/day as the medium dose, calculated on an adult of 60kg, a child of 12 kg.
The medium dosage is as follows: 1.41 g/bag × 2 bag/time × 3 times/day ÷ 60kg × 12kg ÷ 60kg × 6.25 × 1000 ═ 176mg/kg
2.1.2 grouping and dosing
After the adaptation period, 60 rats with good health condition were selected and divided into 60 groups according to the random number table method, 10 rats in each group, and the specific grouping and administration dose are shown in table 1.
TABLE 1 grouping and dosing
Note: the blank control is sterilized water for injection; the positive control is cisapride; the tested substance is Xiaochaihu granules.
2.1.3 preparation of medicinal liquid
Cisapride tablets: 3 mg/kg; 10 ml/kg; 0.3 mg/ml. 1 piece (5mg) + 0.5% CMC-Na → 16.667ml, stored at 4 ℃ and mixed well before use every day.
Xiaochaihu granules: 35.2mg/ml, 17.6mg/ml, 8.8 mg/ml.
950.4mg +27ml sterilized Water for injection → solution (35.2 mg/ml)
12ml solution (i +12ml sterile water for injection → solution (ii) 17.6mg/ml
2.2 Molding
Except for the blank control group, the other groups adopt a method of chronic constraint stress, excessive fatigue and diet loss for molding, namely an FD model. The model rats are placed in a binding box to be bound for 3h every morning, swimming for 10min in the afternoon, fasting is performed every other day, sufficient food is supplied every other day, and the rats are irritated by clamping tails every other day for 30min for 3 weeks continuously. The general conditions of the animals, including hair color, mental state, emotional response, and stool and urine, were observed 1 time per day, and the food intake and body weight of the animals were measured 1 time per week (fig. 2).
2.3 preparation of a nutritional semi-solid paste
8g of milk powder, 5g of sodium carboxymethylcellulose, 4g of sugar, 4g of starch, 3g of activated carbon and 150ml of sterilized water for injection are uniformly stirred to prepare black semisolid paste.
2.4 gastric emptying Rate, Small intestine Propulsion Rate
On day 8, 60 animals were selected and divided into 6 groups of 10 animals each based on weight and food intake, and solvent control, positive control drug or test substance was administered 1 time per day for 14 days according to the above table (Table 1). On day 21, all animals were fasted overnight, on day 22, all animals were given solvent control, positive control drug or test substance, respectively, according to the above table (table 1), 1.5h later, the nutrient paste containing carbon powder was drenched, 30min later, the animals were deeply anaesthetized by inhaling excess CO2, the abdominal cavity was opened, the cardia and pylorus of the stomach were ligated, the stomach tissue was extracted, the total weight of the stomach (S1) and the net weight of the stomach (S2) were weighed, and the gastric emptying rate was calculated. Whole small intestine tissue from the pylorus to the cecum was surgically removed, the total length (L1) and the carbon-dust advance length (L2) were measured and photographed, and the small intestine advance rate was calculated.
The calculation formula of the gastric emptying rate and the small intestine propulsion rate is as follows:
gastric emptying rate (mass of 1- (S1-S2)/nutritional semisolid paste) x 100%
The small intestine propulsion rate is equal to the carbon powder propulsion length/total length multiplied by 100%
2.6 gastric secretion measurement
The contents of the stomach were removed and the total amount of gastric fluid was recorded after centrifugation. Taking 1mL of centrifuged supernatant, adding 1 drop of phenol red indicator, carrying out neutralization titration by using 20mmol/L NaOH, recording the consumed NaOH solution amount, and finally calculating the total acidity and the total acid discharge amount.
The total acidity and total acid output are calculated as follows:
total acidity (nmol/L) ═ volume of NaOH used for titration × 2%
Total acid output (. mu. mol/L) total acidity x amount of gastric acid per hour
2.7 statistics of data
The experimental data were statistically analyzed using SPSS22.0 software, the data were expressed as Mean ± standard deviation (Mean ± SD), the differences between groups were analyzed using one-way anova, and p <0.05 was a significant difference.
3. Results of the experiment
3.1 Effect of Xiaochaihu granules on gastric emptying rate and small intestine propulsion rate of young rat
Compared with the blank control group, the gastric emptying rate and the small intestine advancing rate of the model group model rats are both remarkably reduced (p <0.05vs. blank control group), and the model of dyspepsia of the young rats is successful.
Compared with the model group, the gastric emptying rate of the model rats can be obviously improved by orally intragastrically administering the cisapride with the concentration of 3mg/kg (p <0.01vs. the model group). 176 and 352mg/kg of Xiaochaihu granules also improved the gastric emptying rate of model rats to some extent, but had no statistically significant difference.
Compared with the model group, 88 mg/kg and 176mg/kg of the granule of the bupleurum tenue have no obvious effect of increasing the small intestine propulsion rate of the model rats, and 3mg/kg of the cisapride and 352mg/kg of the granule of the bupleurum tenue have slight improvement but no statistically significant difference on the small intestine propulsion rate of the model rats (Table 2, figure 1).
TABLE 2 Effect of Xiaochaihu granules on gastric emptying Rate and Small intestine Propulsion Rate in Young rats: (
n＝10)
Note: p <0.05, P <0.01, P <0.001vs.
3.2 Effect of Xiaochaihu granules on gastric secretion amount
As shown in Table 3, compared with the blank control group, the total amount of gastric juice, total acidity and total acid output of the model group of young rats are all significantly reduced (P <0.01), indicating that the molding is successful. The total gastric juice, total acidity and total acid output of the young rats of the positive drug group (cisapride) and the test group (small bupleurum particles and high-dose group) are obviously increased (P is less than 0.05, and P is less than 0.01). At the same time, the test groups exhibited dose dependence (fig. 3). The experimental result shows that the bupleurum tenue particles have the function of obviously promoting gastric secretion and can assist the digestion function of young rats.
TABLE 3 Effect of Xiaochaihu granules on gastric secretion in young rats: (
n＝10)
Note: model group vs. blank control group:△P<0.05，△△P<0.01; positive drug, test group vs. model group: p<0.05，**P<0.01。
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed but not to be construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. An application of a Chinese medicinal composition in preparing a medicament for preventing and treating infantile indigestion with food retention is disclosed, wherein the active ingredients of the Chinese medicinal composition are prepared from radix bupleuri, radix scutellariae, ginger processed pinellia tuber, radix codonopsis pilosulae, ginger, liquorice and Chinese date.
2. The use of claim 1, wherein the active ingredients of the traditional Chinese medicine composition are prepared from the following raw materials in parts by weight: 150 +/-5 parts of radix bupleuri, 56 +/-5 parts of radix scutellariae, 56 +/-5 parts of ginger processed pinellia, 56 +/-5 parts of radix codonopsitis, 56 +/-5 parts of ginger, 56 +/-5 parts of liquorice and 56 +/-5 parts of Chinese date.
3. The use of claim 2, wherein the active ingredients of the traditional Chinese medicine composition comprise, in parts by weight: 150 parts of radix bupleuri, 56 parts of scutellaria baicalensis, 56 parts of ginger processed pinellia, 56 parts of codonopsis pilosula, 56 parts of ginger, 56 parts of liquorice and 56 parts of Chinese dates.
4. The use according to any one of claims 1 to 3, wherein the medicament is in the form of a decoction, a fluid extract or a granule.
5. The use according to claim 4, wherein the medicament is in the form of granules.
6. The use of claim 5, wherein the Chinese medicinal composition is XIAOCHAIHU granule.
7. An application of a Chinese medicinal composition in preparing medicine for promoting gastric secretion of children or young rats comprises bupleuri radix, Scutellariae radix, ginger processed pinellia Tuber, radix Codonopsis, rhizoma Zingiberis recens, Glycyrrhrizae radix, and fructus Jujubae as active ingredients.
8. The use of claim 7, wherein the active ingredients of the Chinese medicinal composition are prepared from the following raw materials in parts by weight: 150 +/-5 parts of radix bupleuri, 56 +/-5 parts of radix scutellariae, 56 +/-5 parts of ginger processed pinellia, 56 +/-5 parts of radix codonopsitis, 56 +/-5 parts of ginger, 56 +/-5 parts of liquorice and 56 +/-5 parts of Chinese date.
9. The use of claim 8, wherein the active ingredients of the Chinese medicinal composition comprise, in parts by weight: 150 parts of radix bupleuri, 56 parts of scutellaria baicalensis, 56 parts of ginger processed pinellia, 56 parts of codonopsis pilosula, 56 parts of ginger, 56 parts of liquorice and 56 parts of Chinese dates.
10. The use according to any one of claims 7 to 9, wherein the medicament is in the form of a decoction, a fluid extract or a granule.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021103848417 | 2021-04-09 | ||
| CN202110384841 | 2021-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114425075A true CN114425075A (en) | 2022-05-03 |
Family
ID=81312348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210138796.1A Pending CN114425075A (en) | 2021-04-09 | 2022-02-15 | New application of Xiaochaihu granules in preventing and treating infantile indigestion with food retention |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114425075A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107496884A (en) * | 2017-09-28 | 2017-12-22 | 安徽协和成制药有限公司 | Xiao Chai Hu granules composition and preparation method thereof |
-
2022
- 2022-02-15 CN CN202210138796.1A patent/CN114425075A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107496884A (en) * | 2017-09-28 | 2017-12-22 | 安徽协和成制药有限公司 | Xiao Chai Hu granules composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 郁保生等: "小柴胡汤对功能性消化不良大鼠血管活性肠肽、胃排空及小肠推进率的影响", 《中国实验方剂学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013010383A1 (en) | Intestine-hydrating and laxative drink and preparation method therefor | |
| CN1201786C (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN110787190A (en) | Compound probiotic composition with anti-aging effect and preparation method and application thereof | |
| CN102885348A (en) | Medlar and mulberry beverage with kidney tonifying effect and preparation method thereof | |
| CN115607638B (en) | Traditional Chinese medicine composition for treating infantile indigestion with food retention and preparation method thereof | |
| CN111317775A (en) | Application of preparation for removing food retention and relieving cough for children in preparation of medicine for treating fever and preparation method thereof | |
| CN114949143B (en) | Traditional Chinese medicine composition with effect of treating infantile anorexia and preparation method and application thereof | |
| CN101537143A (en) | Chinese traditional medicine composition for curing chronic gastritis and preparation method thereof | |
| WO2014154008A1 (en) | Purgative composition, preparation method therefor and application thereof | |
| CN104606663B (en) | A kind of Chinese medicine for promoting Recovery and preparation method thereof | |
| CN114425075A (en) | New application of Xiaochaihu granules in preventing and treating infantile indigestion with food retention | |
| CN102614426B (en) | Medicinal preparation for helping digestion and removing stagnation | |
| CN106474413A (en) | A kind of Orally administered composition for treating child's weakness of the spleen and stomach, eating accumulation, anorexia | |
| CN107929413B (en) | Anti-fatigue traditional Chinese medicine composition and application and preparation method thereof | |
| CN105477500A (en) | Traditional Chinese composition regulating intestine and stomach functions of infants and preparing method and preparation thereof | |
| CN111297974A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating food stagnation | |
| CN114129615B (en) | Rabdosia lophanthide composition and application thereof | |
| CN107334927A (en) | A kind of preparation method for the medicine and its chewable tablets for treating children's indigestion and apositia | |
| CN111588788B (en) | Traditional Chinese medicine composition for treating infantile indigestion with phlegm-heat cough and preparation method thereof | |
| CN102886011A (en) | Traditional Chinese medicine for treating dyspepsia | |
| CN103330899A (en) | Medicinal composition for treating infantile anorexia and preparation method thereof | |
| CN102100880A (en) | Chinese medicinal composition for treating ptyalism of children | |
| CN102485269A (en) | Medicinal composition for food digesting and stomach strengthening and preparation method thereof | |
| CN1660135A (en) | Jianerle gel preparation for treating enfant anorexy and preparation method | |
| CN114306393A (en) | New medicine capable of treating cramp, strengthening body and delaying senility and its prepn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220503 |